| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 73.4 | 70.8 |
| Profit before tax | -18.2 | -43.2 |
| Net income | -16.6 | -27.8 |
| EPS (diluted, $ a share) | $-0.17 | $-0.28 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +3.7% |
|---|---|
| Operating margin | -23.5% |
10-Q filed with the SEC, NASDAQ: DCGO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
DocGo Inc.: key numbers
- Share price
- $0.1899Close, Nov 16
- Market cap
- $18.8M
- Shares outstanding
- 98.99MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Health ServicesSIC 8000
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from DocGo Inc.
All →DocGo Executive Compensation
DocGo Inc. entered into a Transition Services and Separation Agreement with CEO Lee Bienstock, who will step down on March 31, 2027. During the transition period, Bienstock will receive a monthly salary of $90,000 and accelerated monthly equity vesting, followed by a $785,000 severance payment. The company is currently conducting a search for a successor CEO as Bienstock's original employment agreement was set to expire at the end of 2026.
- Counterparty
- Lee Bienstock
- Term
- Jan 1, 2027 - Mar 31, 2027
DocGo Financial Results
DocGo reported Q3 2026 revenue of $73.4 million, a slight increase from $70.8 million in the prior year period, driven by record volumes in US medical transportation and phlebotomy. The company narrowed its net loss to $18.1 million and saw GAAP gross margin improve significantly to 29.7% due to profitability initiatives. Additionally, the Board has initiated a search for a new CEO as Lee Bienstock's contract expires at year-end, though he will remain through at least March 2027 to ensure a transition.
- Term
- Q3 2026
DocGo $102M Debt Financing with Perceptive Credit Holdings IV, LP
DocGo Inc. and its subsidiary Ambulnz entered into an Amended and Restated Credit Agreement providing for up to $102 million in term loans, including $52 million in existing debt and $50 million in new and delayed draw facilities. The financing is structured to support the company's pending acquisition of Hicuity Health, Inc., with certain tranches funding upon the merger's closing.
- Value
- $102M
- Counterparty
- Perceptive Credit Holdings IV, LP
- Term
- through Dec 2029